Omar Mian, MD, PhD

/content/dam/www/faculty-photos/M/omar-mian/omar-mian.jpg
Dr. Omar Mian MD, PhD
Faculty Member

Omar Mian, MD, PhD

Associate Professor, Human Biology Division, Fred Hutch

Associate Professor
Human Biology Division, Fred Hutch

Associate Professor, Precision Radiation Sciences Lead, Radiation Oncology Division, Fred Hutch

Associate Professor, Precision Radiation Sciences Lead
Radiation Oncology Division, Fred Hutch

Mail Stop: C1-015

Dr. Omar Mian is a radiation oncologist focused on cancers of the genitourinary tract — primarily bladder, prostate and kidney cancers. As a physician-scientist, he studies the molecular features of these cancers in the lab. He investigates how genes and modifications to gene expression promote the progression of cancer from early-stage, curable forms to more aggressive and treatment-resistant ones with the goal of reversing that process, developing targeted therapies, and reducing therapeutic resistance.

His lab interprets leading-edge  medical imaging techniques that track disease progression and studies patient tumor samples that have survived radiation therapy. The lab also uses cellular and animal model systems of human disease to study the fundamental biology and evolution of common and rare variant carcinomas. Dr. Mian also studies the role of nuclear hormone receptors in regulating DNA repair and resistance to chemotherapy and radiotherapy to identify the tell-tale biological signs of aggressive disease for which new therapies are needed.

Other Appointments & Affiliations

Associate Professor, Department of Radiation Oncology, University of Washington School of Medicine

Associate Professor, Department of Radiation Oncology
University of Washington School of Medicine

Education

MD (Radiation Oncology), Johns Hopkins University Baltimore, 2016

MD, PhD (PhD in the Department of Microbiology and Immunology), VCU School of Medicine, 2011

Research Interests

Molecular mechanisms underlying prostate and bladder cancer initiation, progression, and therapeutic resistance

Interplay between hormone receptor signaling and radiation resistance in prostate cancer

Mechanisms responsible for the transition from androgen-responsive prostate and bladder cancer to small-cell/neuroendocrine cancer

New and emerging radiotherapy delivery technologies, including targeted stereotactic ablative radiation, particle therapy (e.g., proton, neutron, radiopharmaceuticals), and dose rate modulation (e.g., FLASH)

Clinical Expertise

Prostate Cancer

Bladder Cancer

Testicular Cancer

Rare Genitourinary Cancers

“Discoveries in the research laboratory improve the lives of cancer patients and will one day end suffering and death from cancer. Each day, we have the opportunity to push the boundary of what’s possible in cancer care.”

— Dr. Omar Mian

Find a Clinical Trial